better diagnostics
for everyone

Low cost and rapid Point of Care diagnostics 


   PRESS RELEASE         Stockholm, March 16th, 2017

Global Good and Biopromic Partner to Co-Develop Low-Cost Diagnostic Test to Detect Tuberculosis

Biopromic AB announced a technology co-development and license agreement with The Global Good Fund, managed by Intellectual Ventures, to develop a rapid, low-cost and high-sensitivity diagnostic test for the detection of tuberculosis (TB), one of the leading causes of death worldwide. The partnership will combine Global Good’s assay platform with Biopromic’s proprietary technologies in sample preparation and high-sensitivity antibodies to improve the accessibility of accurate TB testing in low- and middle-income countries.


Biopromic specializes in development of:

Rapid immunoassays for infectious disease detection

Ultrasensitive monoclonal antibodies

Production of antigens and reagents for human and veterinarian diagnostics

Contact Us

Biopromic AB

Tomtebodavagen 23A

Contact form

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search